|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1Departments of Anatomy and 2Pharmacology, School of Medical Sciences, University of New South Wales, Sydney, Australia
Submitted 30 August 2007 ; accepted in final form 30 November 2007
| ABSTRACT |
|---|
|
|
|---|
-adrenergic agonists, phenylephrine (PE; 0.03–100 µg/kg) and methoxamine (Meth; 1–300 µg/kg). Unlike PE, Meth is not subject to neuronal reuptake. Ganglionic blockade (0.6 mg/kg chlorisondamine) was used to eliminate the central component of the cardiovascular response. After ganglionic blockade, SCI animals exhibited prolonged vasoconstriction in response to PE in all blood vessels measured compared with those in intact animals (all, P < 0.035). However, the PE dose-response curves obtained after ganglionic blockade revealed no significant difference in the potency between the two groups (all, P > 0.06), indicating that the prolonged vasoconstriction was not due to supersensitivity to PE. In contrast to PE, vascular responses to Meth did not vary between intact and SCI groups (all P > 0.108). These results show the development of a widespread peripheral change producing prolonged vasoconstriction in response to PE, but not Meth, possibly due to reduced neuronal reuptake of PE after SCI. This is the first study to report such a change in blood vessels not only below but also above injury level. Interventions to correct this reduced reuptake may help limit the development of AD.
autonomic dysreflexia; spinal cord transection; phenylephrine; methoxamine
In particular, AD is a disorder that occurs in
85% of patients with high SCI and can lead to permanent deficits or death due to cerebrovascular accidents and myocardial infarction (8, 19). The condition evolves from exaggerated sympathetic reflexes that are triggered by afferent stimulation from areas below the injury level. Common triggers include an overfull bladder and constipation (12, 15, 29). Exaggerated sympathetic activity causes increased vasoconstriction below the injury, resulting in dangerous high blood pressure, which leads to headaches, bradycardia, and cold extremities. Additional symptoms occur due to compensatory baroreflex-mediated vasodilation in blood vessels above the injury level, inducing flushing and sweating (10).
To understand the AD condition, it is important to consider the types of changes that may lead to the development of the disorder. First, there is the obvious loss of supraspinal control pathways, which occurs following SCI. This loss impairs the function of the vasomotor baroreceptor reflex, which would otherwise maintain normal blood pressure through a reduction of sympathetic drive to vascular beds. In addition, following SCI, changes are known to occur within the spinal cord itself, both on preganglionic sympathetic neurons and afferent inputs, with extensive sprouting of CGRP fibers below the level of injury (35). It is thought that this plasticity may also contribute to the exaggerated reflexes seen in the disorder. Second, peripheral vascular changes may develop, especially due to the ongoing low sympathetic tone, which results from a high SCI.
Peripheral changes that may contribute to AD include adrenoceptor supersensitivity (1, 18, 22), altered adrenoceptor density (28), smooth muscle reactivity (37), increased norepinephrine (NE) release (21, 37), and decreased synaptic reuptake of NE (3). In addition, there may be changes in other control mechanisms such as those involving angiotensin and nitric oxide (13, 38).
This paper aims to investigate peripheral vascular changes that develop by 6 wk after a transection at the fourth thoracic spinal level (T4) in the rat, at a time when AD is well established. We have compared the vascular response with the
-adrenergic agonist phenylephrine (PE) before and after ganglionic blockade to separate peripheral from centrally mediated changes. These responses were studied in blood vessels above and below the injury level to assess changes resulting from a direct loss of supraspinal control (blood vessels below injury level) compared with widespread, systemic effects, such as chronic low mean arterial pressure (MAP) (blood vessels both above and below injury level). This is the first time that such a comparison has been made following ganglionic blockade. Finally, the responses to PE were compared with methoxamine (Meth), another
-adrenergic agonist that, unlike PE, is not a substrate for neuronal reuptake. This was used to test for any alteration in NE reuptake mechanisms.
| METHODS |
|---|
|
|
|---|
Spinal cord transection.
Rats in the SCI group (n = 7) were rendered paraplegic by a complete transection of the spinal cord at T4 under anesthesia (ketamine and xylazine, 100 mg + 50 mg/kg ip). After the dissection of the superficial and deep muscles of the back, a laminectomy of the third thoracic vertebra was performed to reveal the T4 spinal segment, which was cut with microscissors. Complete transection was confirmed with a scalpel blade and by observation of the cut cord surfaces under the dissecting microscope. After transection, a gap of
2 mm was present between the rostral and caudal ends of the cord. A piece of gelfoam was inserted to fill the gap and reduce bleeding. Gelfoam was also placed on the dorsal surface of the cord. Finally, the muscle tissue and skin were sutured in layers.
Postoperative care. Rats received an antibiotic (Keflin, 100 mg/ml sc) twice daily until no sign of urinary infection was seen for 3 consecutive days. The animals also received an analgesic (carprofen, 50 mg/kg sc) daily for 3 days and saline solution (5 ml of 0.9% saline sc) to provide hydration until each rat could drink following the surgery. Manual emptying of the urinary bladder was carried out three times a day until the rats developed automatic bladder emptying (usually 2 wk posttransection). The room temperature was maintained at 27–28°C for 7 days, and rat temperature was measured regularly until a normal temperature was maintained. Other interventions included administering a laxative (Catlax; Novartis Australasia) if bowel impaction occurred. Dietary supplements were given to treat weight loss. The rats were weighed daily and monitored for skin lesions or swelling. Any rat with a severe lesion was euthanized.
Experimental protocol. After SCI, all rats were allowed a 6-wk recovery period. At this point AD, in response to colorectal distension, was present (change in MAP of at least 25 mmHg) (20). Intact rats (n = 7) were also housed during this period to serve as controls for age and adaptation to housing.
Terminal experiment. At the 6-wk time point, both the intact and SCI rats underwent the terminal experiment. The procedure was conducted under pentobarbitone sodium anesthesia involving an initial intraperitoneal injection (45 mg/kg) and maintenance with continuous intravenous infusion (15 mg·kg–1·h–1). Animals were maintained at 37°C on a homeostatic heating pad. A tracheostomy was performed and a tracheal tube was inserted and connected to a respirator and CO2 monitor. The femoral artery was cannulated and connected to a pressure transducer to allow for the extraction of MAP and heart rate (HR) by a MacLab data acquisition system (ADInstruments, Bella Vista, Australia). One femoral and one jugular vein were cannulated for the administration of agonists and anesthetic, respectively. Ultrasonic Doppler-flow probes (Iowa Doppler Products, Iowa City, IA) were placed on arteries above (common carotid and brachial) and below (renal and femoral) the T4 level for the recording of relative blood flows with a Doppler flowmeter. The brachial and femoral arteries supply muscular/cutaneous territories, whereas the renal and carotid arteries supply mostly viscera and the brain. Vascular conductance (blood flow/MAP) was calculated and displayed in real time by the MacLab software (Chart 5.0; ADInstruments).
Adrenergic agonist injections.
The terminal experiment commenced with verification of the real zero of the Doppler blood flow measurements obtained by occluding the artery for an appropriate interval (5 s). An intermediate dose of the
-adrenergic agonist PE (10 µg/kg in 0.3 ml heparinized saline iv; Sigma) was given first as a bolus injection (rate of 0.1 ml/s) to allow a recording of the full time course of the cardiovascular response. The period studied started 1 min before injection and lasted until blood pressure returned to normal. The ganglionic blocker chlorisondamine (0.6 mg/kg iv; Sigma) was then administered to produce complete ganglionic blockade. Atropine methyl nitrate (4 mg/kg iv; Apex) was also administered to ensure complete cardiac blockade. The same intermediate dose of PE was repeated following ganglionic blockade and recorded in the same way. After this, 10 different doses of PE (0.03–100 µg/kg iv) were administered in random order to allow a compilation of dose-response curves. Between each dose, sufficient time was left to allow MAP to return to baseline (at least 7 min). Finally, Meth injections were given. As with the PE responses, it involved an initial administration of an intermediate dose (100 µg/kg; Sigma) followed by six randomized doses (1–300 µg/kg iv) to allow compilation of dose-response curves. Some animals did not receive both PE and Meth because of Doppler-probe signal problems or condition deterioration (e.g., respiratory difficulty) due to the long period of anesthesia. For this reason, the animal numbers may vary for different responses. Furthermore, in a small number of animals (intact, n = 2; SCI, n = 2), the Meth injections were given first after ganglionic blockade to check for any time effect. Since no difference was observed, all responses were pooled together.
Analysis of the time course of the response. A time course analysis comparing intact and SCI animals was performed for the response to the injection of intermediate doses of PE (10 µg/kg) before and after ganglionic blockade and Meth (100 µg/kg) after ganglionic blockade. The response of each animal was the average of three repeated injections of the agonist; changes in conductance were expressed as percent change from baseline, and values were sampled every 5 s. We analyzed the overall responses of each parameter over time with a repeated-measures ANOVA, where the repeated measure was time and the test factor was SCI. We also analyzed the magnitude and duration of the response to each parameter by extracting the peak response and time taken for conductance to recover by 75% of the peak change (T75) from the original recordings from each animal. Peak and T75 values were compared using a one-way ANOVA in which the test factor was SCI. Effects were considered significant if P < 0.05.
Analysis of dose-response curves to compare sensitivity with adrenergic agonists. The maximum decreases in vascular conductance were extracted from the response to each dose of PE and Meth and expressed as a percentage of baseline. These values were then expressed against the log agonist dose to produce sigmoidal dose-response curves using nonlinear regression analysis within Prism 4.0 (GraphPad) software. The log EC50 and maximal response values were determined from these dose-response curves. The mean log EC50 and standard error for intact and SCI groups were calculated as well as the geometric mean of the EC50, and these values were compared by t-tests, where P values of <0.05 were taken to indicate a significant difference between the intact and SCI parameters.
| RESULTS |
|---|
|
|
|---|
|
|
|
|
-adrenergic agonists may be attributed to the fact that Meth is not subject to neuronal reuptake.
|
| DISCUSSION |
|---|
|
|
|---|
Changes in baseline blood pressure after SCI. Under anesthesia, SCI animals had a markedly reduced baseline MAP compared with intact animals. This observation is consistent with previous reports of lowered basal MAP in SCI animals (20) and patients (2, 23), particularly following anesthetic administration (11, 34). This hypotension is a result of reduced vasomotor tone following SCI due to a lower level of basal sympathetic tone below the level of the transection (23, 30). Accordingly, ganglionic blockade had little effect on SCI animals (which were already partially decentralized) but markedly reduced MAP in intact animals, bringing the two groups down to the same baseline level. Although it could be desirable to perform the study in conscious animals to avoid the effect of an anesthetic on cardiovascular reflexes and vasomotor tone, the use of ganglionic blockade has made the two groups comparable.
Changes in vascular conductance responses after SCI. The first experiment showed that intravenous injections of PE in SCI animals produced greater and longer-lasting vasoconstrictions than in intact animals. This effect is not surprising for vascular beds located below the level of the lesion since the vasomotor preganglionic sympathetic neurons that control these beds have lost the supraspinal connections that mediate the baroreceptor reflex. This leads to the vasoconstriction in the femoral and renal arteries being greater and longer due to the loss of reflex withdrawal of sympathetic tone in response to the rise in blood pressure. However, the same effect was also observed in the brachial and carotid arteries, which were above the level of the lesion and would have had intact baroreflex modulation. This surprising observation raised the possibility that the long-lasting vasoconstriction was, perhaps, not of central but of peripheral origin.
The peripheral origin of the prolonged vasoconstriction was confirmed after ganglionic blockade because PE stimulation still resulted in longer-lasting vasoconstriction in SCI compared with intact animals, despite the complete removal of central vasomotor regulation. Furthermore, the effect was observed in all four vasculatures, suggesting that a general, widespread hyperreactivity to PE had developed in chronic SCI animals.
To better characterize the prolonged vasoconstriction, dose-response curves to PE under ganglionic blockade were constructed. Except for an increase in the maximal response in the SCI carotid artery, the curves were the same in intact and SCI animals. The analysis revealed no significant change in EC50 between the two groups for any of the blood vessels tested, indicating that the exaggerated blood vessel responses were not due to an increased sensitivity to PE. The increase in the maximal response observed in the carotid artery may reflect changes in the relative proportion of each of the
1-adrenoceptor subtypes expressed in the SCI carotid artery. In particular, this increase may be due to changes in the ratio of
1A- to
1B-adrenoceptors since it has been shown in in vitro studies that coexpressing
1A- and
1B-adrenoceptors leads to a synergistic increase in PE maximal response (but not Meth maximal response) compared with the expression of the
1A-adrenoceptor alone (14).
Exaggerated responses to PE or NE have previously been shown in spinally injured tetraplegic patients (1, 18, 25). Studies have found that PE causes exaggerated pressor responses in SCI patients compared with intact subjects (18, 25), and one study reported greater vasoconstriction of the dorsal foot vein following the application of NE (1). Although Arnold et al. (1) conclude that the exaggerated responses seen in their study are due to the development of supersensitive adrenoceptors following SCI, their results could also result from a decreased level of NE reuptake following SCI. The use of the
-adrenergic agonist Meth, which unlike NE and PE, is not a substrate for the NE transporter NET1 (33), or the inhibition of NET1 with a selective NET1 inhibitor (e.g., desipramine) would be necessary to ascertain whether the exaggerated responses reported are due to adrenoceptor changes or impaired neuronal reuptake of the agonist.
Extensive studies by McLachlan and colleagues (3, 36, 37) have previously examined this issue using an in vitro dissected artery preparation. Studies by this group have reported the development of adrenoceptor supersensitivity of the mesenteric (3) but not tail (36, 37) arteries following chronic spinal cord transection and sympathetic dennervation. A recent study by this group has also used the adrenergic agonist Meth and the NET1 blocker despiramine to remove the variable of neuronal agonist reuptake from the responses of intact and denervated arteries. They reported that although the mesenteric artery of spinally transected animals showed a leftward shift of PE dose-response curves, dose-response curves produced for Meth, and PE following NET1 blockade, did not differ between intact and transected arteries (3).
To distinguish between these variables in our study, we also tested Meth in place of PE for the final measurements. In response to Meth, no significant difference was observed between the intact and SCI groups. There are two differences between the actions of Meth and PE in producing vasoconstriction; these are that Meth is not a substrate for NET1 (33) and that although PE is known to act with similar potencies at
1A-,
1B-, and
1D-adrenoceptors, Meth is 20 times more potent at the
1A-subtype receptors than
1B- or
1D-subtype receptors (27). The fact that, following ganglionic blockade, brachial, femoral, and renal arteries of SCI animals showed a longer duration of vasoconstriction (longer T75) than intact animals while having similar peak conductance changes suggests a slower rate of recovery following PE in SCI subjects. This supports the hypothesis of a decrease in neuronal reuptake of PE following SCI, leading to a prolonged saturation of postsynaptic adrenoceptors and prolonged vasoconstriction. However, this may not be the case in the carotid artery if, as postulated before, the increased response was due to a relative increase in the density of the
1B-receptor, since Meth has little effect on the
1B-receptor. This is supported by the fact that in the carotid artery response to PE after ganglionic blockade, the size of the increase in T75 was the same as the increase in peak change in conductance (1.9- and 2.3-fold difference, respectively), indicating that the rate of change of the response was actually the same in intact and SCI responses. It appears that in that case, the prolonged T75 is a result of the greater peak change in conductance rather than an altered degree of neuronal reuptake. Further experiments could use a NET1 inhibitor during responses to PE to test the hypothesis that reduced neuronal NE reuptake is the mechanism of the change in the brachial, femoral, and renal arteries within our study.
Although our study found prolonged vascular conductance responses to PE following SCI, we did not find significantly different PE dose-response curves for SCI and intact arteries like Brock et al. (3) did. Possible reasons for the lack of adrenoceptor supersensitivity found in our study compared with that found in Brock et al. (3) include our in vivo systemic injection protocol compared with the direct agonist application technique used by Brock et al. (3). In addition, the artery type examined may affect results, considering that McLachlan and colleagues have reported that although the mesenteric artery shows supersensitivity to PE at week 7 (3), the tail artery does not (36, 37).
A widespread effect. This is the first study to report vascular changes both above and below injury level following high-level SCI. In fact, no other study has compared the peripheral responses of blood vessels above and below injury level following SCI after ganglionic blockade in vivo or in vitro. Most of the studies that have previously compared the responses of blood vessels above and below injury level in spinal patients (without the use of ganglionic blockade) have found that although vascular adaptations develop in regions below the injury level, they do not necessarily occur above the injury (6, 7). However, most of the subjects in these studies had injuries below T6, which is generally considered the critical level for development of AD and lowered basal MAP. One study of ultrasound images taken of the radial and posterior tibial arteries of SCI patients with injuries ranging from T2 to T11 (half with injuries below T6) reported that both arteries have impaired vascular relaxation in response to increased blood flow following occlusion compared with able-bodied subjects (31). This suggests that peripheral changes can occur in blood vessels above the SCI lesion, even in cases of relatively low-level SCI.
In a study of SCI patients with impaired sympathetic control (injuries from C7 to T4), Karlsson et al. (16) examined the blood pressure, NE spillover, NE clearance, and blood flow in the arm and leg at baseline and during bladder stimulation to produce AD. They found no significant difference in baseline levels between SCI and control groups; however, during bladder stimulation, SCI patients exhibited elevated blood pressure and leg NE spillover with significantly decreased leg blood flow. Interestingly, although NE spillover in the arm did not change during bladder stimulation, arm blood flow still decreased by the same relative amount as the leg. The fact that this decrease did not reach significance may be due to greater variability in the responses of the arm. Nevertheless, it suggests that blood vessels above the level of injury in high-SCI patients can respond vigorously to circulating catecholamines even though they have an intact vasomotor baroreflex.
The fact that enhanced PE responses were observed in blood vessels above and below injury level after SCI in our study suggests that the mechanisms producing the peripheral changes must be acting on vasculature throughout the body. These mechanisms include an impaired reuptake of PE and, in some beds such as the carotid vascular bed, a possible change in
1-receptor subtype density. The origin of these peripheral changes is likely to be systemic and secondary to the consequences of SCI on the entire organism. The most obvious and likely explanation would be that these changes are an adaptation to compensate for the lower basal blood pressure and reduced level of circulating NE in the vascular system. Although this adaptation may be beneficial at rest to help maintain MAP, it also causes hyperreactivity to circulating catecholamines that may be released during episodes of AD.
Conclusions. Taken together, our results suggest that widespread peripheral changes, including a decreased level of presynaptic reuptake of NE, occur following SCI, leading to exaggerated responses to NE. These widespread changes probably develop due to the lower basal MAP and NE levels present following high-level SCI and are likely to contribute to the development of AD in this group of patients. Further studies are needed to confirm the cause and time course of the development of the reduced reuptake and, hence, establish its role in the development of AD in animals and patients. Furthermore, such reduced reuptake could be a target of future interventions aimed at alleviating the symptoms and morbidity produced by AD.
| GRANTS |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. S. Laird, P. Carrive, and P. M. E. Waite Effect of Treadmill Training on Autonomic Dysreflexia in Spinal Cord--Injured Rats Neurorehabil Neural Repair, November 1, 2009; 23(9): 910 - 920. [Abstract] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |